

Debrief from call with Joel



Verhoeven, Michael <Michael.Verhoeve@bain.com>

To Erin Cosgriff (cosgriff.erin@gmail.com); pjv280380@hotmail.com

Cc verhoeven@gmail.com

Reply

Reply All

Forward



Wed 20/06/2018 2:48 PM

Here's the quick summary of my discussion with Joel. I may have some of the details of this slightly off so don't read it too forensically – but the substance is right.

Pat – let me know if any of this is inconsistent with what you're hearing from South Eastern and/or Farnbach – or if there is any significant issue here.

- JA recommended Patrick's admission in response to his distress (calling JA every day)
 - He clarified this after I suggested Pat admitted himself in response to the distress/concern related to reducing his medication – I had misinterpreted events
- JA recommended to PF the following for Pat's admission:
 - Reduce and cease any stimulant (e.g. Vyvanse or dex)
 - Reduce and cease any Valium (believe it was likely being over-used, with limited benefit, and has addictive side effects)
 - Shift instead to an anti-psychotic (e.g. alternative to Latuda)
 - Overall logic is to remove stimulant and Valium, and instead treat the anxiety with anti-psychotic
 - Alternative diagnosis of bi-polar would not change this path
- JA does not have close oversight or control of in-patient management (that is PF's responsibility), but he has made the above recommendation clear
- JA recommends that he sees Pat before he is formally discharged
- JA recommends that after current admission (i.e. when off stimulant and Valium, and then subsequently discharged) we reconsider the best treatment path
 - E.g. I asked whether alternative in-patient treatment might be advised – he recognised that South Eastern is new with limited extra services, and therefore there may be more appropriate alternatives

Thanks, Mick.

Michael Verhoeven

Partner

Bain & Company, Inc. | Level 37, 120 Collins St | Melbourne VIC 3000 | Australia

mob: +61 409 237 886

Web: www.bain.com | Email: Michael.Verhoeven@Bain.com

This e-mail, including any attachments, contains confidential information of Bain & Company, Inc. ("Bain") and/or its clients. It may be read, copied and used only by the intended recipient. Any use by a person other than its intended recipient, or by the recipient but for purposes other than the intended purpose, is strictly prohibited. If you received this e-mail in error, please contact the sender and then destroy this e-mail. Opinions, conclusions and other information in this message that do not relate to the official business of Bain shall be understood to be neither given nor endorsed by Bain.